Shield to Present at Baird Healthcare Conference

RNS Number : 3693P

Shield Therapeutics PLC

31 August 2017

 

Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017

London, UK, 31 August 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive Officer, will present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017 at 9:05 AM ET in New York. Mr. Sterritt will give a corporate overview, review the Company's late-stage and commercial product portfolio, and provide an update on upcoming milestones, including key clinical trial readouts and potential subsequent regulatory submission.

An audio webcast of the presentation will be available in the events section of the Company's website, or by clicking here. A replay will be available for a limited time following the presentation.

About Shield Therapeutics

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals, which address areas of unmet medical need.  The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.

For further information please contact:

Shield Therapeutics plc                                                                     [phone]             

Joanne Estell, Chief Financial Officer

Karl Keegan, Corporate Development Director

Nominated Adviser and Joint Broker                                             [phone]

Liberum Capital Limited                     

Christopher Britton

Steve Pearce

Jonathan Wilkes-Green                      

Joint Broker                                                                                       [phone]

Peel Hunt LLP             

James Steel

Alastair Rae   

Oliver Jackson

Financial PR Adviser                                                                          [phone]

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

[e-mail]

U.S Investor Relations                                                                        + 1 (212)-599-1265

Lazar Partners Ltd.

Matthew Ventimiglia

[e-mail]

 

END

 

 

MSCDMGFRMGFGNZZ